- Home
- CATX
as 11-15-2024 4:00pm EST
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 782.7M | IPO Year: | N/A |
| Target Price: | $21.63 | AVG Volume (30 days): | 737.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $19.10 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,557,000 | Revenue Growth: | -73.52% |
| Revenue Growth (this year): | -15.83% | Revenue Growth (next year): | -42.57% |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?
![Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024](https://cdn.finquota.com/news/5e5eb61c-878e-4c32-8649-5aa9ff56b2b0.jpg)
GlobeNewswire
2 days ago
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
MT Newswires
4 days ago
RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk
Associated Press Finance
5 days ago
Perspective Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
5 days ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
GlobeNewswire
17 days ago
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
GlobeNewswire
19 days ago
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
MT Newswires
24 days ago
UBS Initiates Perspective Therapeutics at Buy With $20 Price Target
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.